Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,181 | 0,192 | 31.07. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
12.06. | VIVA BIOTECH (01873): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 12, 2025 | 1 | HKEx | ||
04.06. | VIVA BIOTECH (01873): SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO CONNECTED TRANSACTION | - | HKEx | ||
30.05. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
28.05. | VIVA BIOTECH (01873): CONNECTED TRANSACTION INVESTMENT IN LIMITED PARTNERSHIP FUND | 1 | HKEx | ||
15.05. | Viva Biotech Launches the AI-Driven Drug Discovery Platform, Transforming New Drug R&D Logic, Enabling One-Stop Innovative Drug Discovery | 307 | PR Newswire | SHANGHAI, May 15, 2025 /PRNewswire/ -- On May 13, 2025, Viva Biotech successfully held the AIDD platform launch event "Enchantment of Drug Discovery," unveiling the advanced and comprehensive... ► Artikel lesen | |
VIVA BIOTECH Aktie jetzt für 0€ handeln | |||||
06.05. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
24.04. | VIVA BIOTECH (01873): 2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | - | HKEx | ||
24.04. | VIVA BIOTECH (01873): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING | 1 | HKEx | ||
24.04. | VIVA BIOTECH (01873): NOTICE OF ANNUAL GENERAL MEETING | 1 | HKEx | ||
24.04. | VIVA BIOTECH (01873): PROPOSED RE-ELECTION OF RETIRING DIRECTORS PROPOSED RE-APPOINTMENT OF AUDITOR PROPOSALS FOR GRANTING OF GENERAL MANDATES TO ISSUE ... | - | HKEx | ||
24.04. | VIVA BIOTECH (01873): 2024 ANNUAL REPORT | - | HKEx | ||
07.04. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
28.03. | Viva Biotech's Wholly-Owned Subsidiary Langhua Pharmaceutical Successfully Passes U.S. FDA On-Site Inspection | 334 | PR Newswire | SHANGHAI, March 28, 2025 /PRNewswire/ -- Zhejiang Langhua Pharmaceutical Co., Ltd. ("Langhua Pharmaceutical"), a wholly-owned subsidiary of Viva Biotech Holdings... ► Artikel lesen | |
27.03. | Viva Biotech Announces 2024 Annual Results: Significantly Rebounding in Performance with New Stage ahead, AI Leads to a New Era of Novel Drug R&D | 129 | PR Newswire | Highlights of Annual Results for the Year Ended December 31, 2024 Revenue reached RMB1,986.7 million Gross profit amounted to RMB687.4 million Net profit recorded... ► Artikel lesen | |
27.03. | VIVA BIOTECH (01873): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE | 1 | HKEx | ||
27.03. | VIVA BIOTECH (01873): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION | - | HKEx | ||
27.03. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
27.03. | VIVA BIOTECH (01873): VOLUNTARY ANNOUNCEMENT ANNOUNCEMENT ON THE PASSING OF U.S. FDA ON-SITE INSPECTION BY LANGHUA PHARMACEUTICAL, A WHOLLY-OWNED SUBSIDIARY | 1 | HKEx | ||
27.03. | VIVA BIOTECH (01873): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024 AND CHANGE OF COMPOSITION OF THE NOMINATION COMMITTEE | 3 | HKEx | ||
17.03. | VIVA BIOTECH (01873): DATE OF BOARD MEETING | 1 | HKEx |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
VALNEVA | 3,214 | +0,37 % | BioTech wird zu Gold: Wer schluckt wen oder was? Auf der Liste sind Evotec, BioNxt, Valneva und Formycon! | Der BioTech-Sektor blickt mit Argusaugen auf das Zinsniveau der Notenbanken. Aktuell allerdings scheint die Inflation noch etwas zu hoch, um massive Senkungen zu erwarten. So hat auch die EZB gestern... ► Artikel lesen | |
NOVONESIS | 56,70 | +0,04 % | Novonesis (Novozymes A/S): Biosolutions could create more than 600,000 jobs and unlock hundreds of billions in growth for Europe | Biosolutions could create more than 600,000 jobs and unlock hundreds of billions in growth for Europe
A new report reveals that biosolutions could generate EUR 133 billion in economic gains and... ► Artikel lesen | |
GENMAB | 194,00 | +2,00 % | Genmab A/S: Genmab Announces Net Sales of DARZALEX (daratumumab) for Second Quarter of 2025 | Company Announcement Net sales of DARZALEX® in the second quarter of 2025 totaled USD 3,539 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen... ► Artikel lesen | |
ARBUTUS BIOPHARMA | 2,954 | +2,93 % | Arbutus Biopharma Corporation: Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update | Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S. mRNA-LNP vaccine litigation scheduled for September... ► Artikel lesen | |
BEONE MEDICINES | 264,00 | 0,00 % | BeOne Medicines Ltd.: BeOne Medicines erhält von der Europäischen Arzneimittelagentur PRIME-Kennzeichnung für BGB-16673 in Waldenström's Makroglobulinämie | Entscheidung beweist das Potenzial von BGB-16673, ein experimenteller, potenziell erstklassiger BTK-Degrader, der den Widerstand in B-Zell-Malignomen heruntersetzen und Reaktionen vertiefen soll... ► Artikel lesen | |
SINO BIOPHARM | 0,818 | -0,94 % | Minimales Kursplus bei der Sino Biopharmaceutical-Aktie (0,773 €) | Am Aktienmarkt ist das Wertpapier von Sino Biopharmaceutical zur Stunde unauffällig. Der jüngste Kurs betrug 0,77 Euro. Kaum auffällig ist derzeit an der Börse der Kurs von Sino Biopharmaceutical. Das... ► Artikel lesen | |
MOLECULIN BIOTECH | 0,510 | -100,00 % | Moleculin Biotech, Inc.: Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin | - New patent enhances market position in Europe HOUSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company... ► Artikel lesen | |
VERICEL | 31,800 | +3,25 % | Vericel Corporation: Vericel Reports Second Quarter 2025 Financial Results | Total Revenue Growth of 20% to $63.2 Million, with MACI Revenue Growth of 21% to $53.5 Million Gross Margin Increased More than 400 Basis Points to 74% Adjusted EBITDA Growth of 112% to $13.4 Million... ► Artikel lesen | |
SENSEI BIOTHERAPEUTICS | 7,410 | +3,64 % | Sensei Biotherapeutics präsentiert Daten zu Krebstherapie auf dem ESMO-Kongress 2025 | ||
MUSTGROW BIOLOGICS | 0,448 | +2,52 % | MustGrow Biologics Corp.: MustGrow Announces Non-Brokered LIFE Offering of up to $3 Million, Proposed Repricing of Warrants, and Shares for Debt Settlement Offer to Debentureholders | Saskatoon, Saskatchewan--(Newsfile Corp. - July 30, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), is pleased to announce the following: (i)... ► Artikel lesen | |
ZAI LAB LTD ADR | 32,600 | -1,81 % | ZAI LAB (09688): NOTICE OF AUDIT COMMITTEE ACTION AND DATE OF PUBLICATION OF 2025 INTERIM RESULTS ANNOUNCEMENT | ||
BIOXCEL THERAPEUTICS | 1,360 | -100,00 % | Mizuho slashes BioXcel Therapeutics stock price target to $2 from $16 | ||
REGENXBIO | 7,700 | +3,36 % | REGENXBIO Inc.: REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy | Construct including CT domain demonstrated higher levels of microdystrophin protein, increased muscle force, and improved resistance to damage in mice lacking... ► Artikel lesen | |
AKEBIA | 3,282 | +1,67 % | Akebia Therapeutics, Inc.: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease... ► Artikel lesen | |
CSTONE PHARMACEUTICALS | 0,800 | +1,27 % | CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - ESMO 2025: CSTONE TO DEBUT CS2009 CLINICAL DATA AND CS5001 TRIAL DESIGN |